Taken together, the present work from Li et al (summarized in Fig 1) deepens our knowledge on cardiac growth regulation, and the NCoR1/MEF2/class II HDACs axis may in the future be a target for new therapies to inhibit pathological cardiac hypertrophy. This evidence concerns the gene MEF2A and cardiac hypertrophy.